Companies overseeing prescription benefits poised for growth

NewsGuard 100/100 Score

Pharmacy benefit management companies, the third-party administrators for prescription drug programs, have seen a boom in business. NPR reports they are "now poised for even more growth, as baby boomers age and Congress prepares to insure more Americans. ..."

"The PBM industry emerged when health plans started covering prescriptions. Big insurers found negotiating with pharmaceutical companies to be a hassle, so PBMs began cropping up, offering to take that task off of their hands. Today, PBMs cover more than 200 million Americans. With the ability to create or eliminate large numbers of customers, Express Scripts scientist Bob Nease says, PBMs have the clout to check the power of drug companies." PBMs tend to push less-expensive generic drugs and encourage customers to use mail-order prescription companies (Sepic, 1/20).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Early life stress may underlie a pathophysiological exacerbation of postpartum depression